Drug Resistance in Epilepsy: The Role of the Blood–Brain Barrier
The DOI matches its Crossref record.
Abstract
The blood-brain barrier (BBB) is formed by the endothelial cells lining the brain microvessels. Complex tight junctions linking adjacent endothelial cells make brain capillaries around 100 times tighter than peripheral capillaries to small hydrophilic molecules. As a result, drugs required to act in the brain, including anti-epileptic drugs (AEDs), have generally been made lipophilic, and are thus able to cross the brain endothelium via the lipid membranes. However, such lipophilic drugs are potential substrates for efflux carriers of the BBB, particularly P glycoprotein (Pgp), predominantly located on the endothelial luminal membrane. It is estimated that up to 50% of drug candidates may be substrates for Pgp. The barrier phenotype of the brain endothelium is induced and maintained by chemical factors released by brain cells, particularly perivascular astrocytic end feet. In several neuropathological conditions, the BBB is disturbed, either as a result of pathology of the endothelium, or of the cells responsible for barrier induction and maintenance. During epileptic attacks, there may be transient BBB opening in the epileptogenic focus. There is evidence that under such pathological conditions, 'second line defence' mechanisms in perivascular glia may be up-regulated, including expression of Pgp and other drug efflux transporters. This complicates interpretation of drug resistance in epilepsy, and therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Self-citationStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Self-citationDaneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
“Up-regulation of Mdr1 has also been associated with drug-resistant epilepsy and tumors (Potschka et al. 2001; Abbott et al. 2002).”
BackgroundDrug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
The blood–brain barrier in health and disease
Daneman, R. (2012) · Annals of Neurology · doi:10.1002/ana.23648 · Cited by 754
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs
Löscher, W., & Potschka, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.7 · Cited by 409
The Blood–Brain Barrier and Epilepsy
Oby, E., & Janigro, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00817.x · Cited by 388
Self-citationCerebrospinal fluid dynamics and intracranial pressure elevation in neurological diseases
Bothwell, S. W., Janigro, D., & Patabendige, A. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0129-6 · Cited by 319
Self-citationIn Vitro Blood–Brain Barrier Models: Current and Perspective Technologies
Naik, P., & Cucullo, L. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23022 · Cited by 288
Antagonism of peripheral inflammation reduces the severity of status epilepticus
Marchi, N., Fan, Q., Ghosh, C., Fazio, V., Bertolini, F., Betto, G., Batra, A., Carlton, E., Najm, I., Granata, T., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.002 · Cited by 284
Self-citationLöscher, W., & Friedman, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020591 · Cited by 229
“It is assumed that up to 50% of drug candidates may be substrates for Pgp [57].”
BackgroundAronica, E., Gorter, J. A., Jansen, G. H., van Veelen, C. W. M., van Rijen, P. C., Leenstra, S., Ramkema, M., Scheffer, G. L., Scheper, R. J., & Troost, D. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00992-2 · Cited by 197
Cucullo, L., Hossain, M., Rapp, E., Manders, T., Marchi, N., & Janigro, D. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.00960.x · Cited by 162
“Multiple drug resistance is characterized by insensitivity to a broad spectrum of drugs with different chemical nature (Dombrowski et al., 2001; Abbott et al., 2002; Marroni et al., 2003b; Loscher, 2005), presumably acting on different receptors and/or by different mechanisms.”
BackgroundSelf-citation
Metadata
- Authors
- Abbott, N. J., Khan, E. U., Rollinson, C. M. S., Reichel, A., Janigro, D., Dombrowski, S. M., Dobbie, M. S., & Begley, D. J.
- Venue
- Novartis Foundation Symposia
- Publisher
- Wiley
- Published
- 2002-03-25
- Volume
- 243
- Pages
- 38-53
- ISSN
- 1528-2511 (ISSN-L)
- 1935-4657
- OpenAlex
- W1523564114
- Cited by
- 109
- References
- 0
- Type
- other
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.